Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

RationaleAlthough psilocybin has been used for centuries for religious purposes, little is known scientifically about its acute and persisting effects.ObjectivesThis double-blind study evaluated the acute and longer-term psychological effects of a high dose of psilocybin relative to a comparison compound administered under comfortable, supportive conditions.Materials and methodsThe participants were hallucinogen-naïve adults reporting regular participation in religious or spiritual activities. Two or three sessions were conducted at 2-month intervals. Thirty volunteers received orally administered psilocybin (30 mg/70 kg) and methylphenidate hydrochloride (40 mg/70 kg) in counterbalanced order. To obscure the study design, six additional volunteers received methylphenidate in the first two sessions and unblinded psilocybin in a third session. The 8-h sessions were conducted individually. Volunteers were encouraged to close their eyes and direct their attention inward. Study monitors rated volunteers’ behavior during sessions. Volunteers completed questionnaires assessing drug effects and mystical experience immediately after and 2 months after sessions. Community observers rated changes in the volunteer’s attitudes and behavior.ResultsPsilocybin produced a range of acute perceptual changes, subjective experiences, and labile moods including anxiety. Psilocybin also increased measures of mystical experience. At 2 months, the volunteers rated the psilocybin experience as having substantial personal meaning and spiritual significance and attributed to the experience sustained positive changes in attitudes and behavior consistent with changes rated by community observers.ConclusionsWhen administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences. The ability to occasion such experiences prospectively will allow rigorous scientific investigations of their causes and consequences.

[1]  J. Woods,et al.  Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys , 2004, Behavioural pharmacology.

[2]  D. Wulff.  The Psychology of Religion: Classic and Contemporary Views , 1991 .

[3]  Hollister Le.  Clinical, biochemical and psychologic effects of psilocybin. , 1961 .

[4]  Peter C. Hill,et al.  The psychology of religion: An empirical approach, 4th ed. , 1996 .

[5]  D. Wulff.  Psychology of Religion: Classic and Contemporary , 1996 .

[6]  H. D. Abraham,et al.  The Psychopharmacology of Hallucinogens , 1996, Neuropsychopharmacology.

[7]  R. Piedmont,et al.  Cross-Cultural Generalizability of the Spiritual Transcendence Scale in India , 2002 .

[8]  W. Pahnke.  Psychedelic drugs and mystical experience. , 1969, International psychiatry clinics.

[9]  David Watson,et al.  The PANAS-X manual for the positive and negative affect schedule , 1994 .

[10]  D. Watson,et al.  Measurement and mismeasurement of mood: recurrent and emergent issues. , 1997, Journal of personality assessment.

[11]  R. Yensen,et al.  The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients , 1977 .

[12]  S. Malitz,et al.  Some observations on psilocybin, a new hallucinogen, in volunteer subjects. , 1960, Comprehensive psychiatry.

[13]  A. Rodríguez-Fornells,et al.  Psychometric assessment of the Hallucinogen Rating Scale. , 2001, Drug and alcohol dependence.

[14]  J. Ott.  The Wondrous Mushroom: Mycolatry in Mesoamerica , 1981 .

[15]  R. Gorsuch,et al.  Psychology of Religion , 1988 .

[16]  L. Chait.  Reinforcing and subjective effects of methylphenidate in humans , 1994, Behavioural pharmacology.

[17]  N. Smart,et al.  Mysticism and Philosophy. , 1963 .

[18]  R. E. Schultes.  Halluzinogene — psychische grenzzustande in forschung und psychotherapie: Hanscarl Leuner, Verlag Hans Huber, Bern, 1981, 458 pp., 33 figs., tables 5 (DM48.00, approx. US$22.00) , 1984 .

[19]  D. Jasinski,et al.  Assessment of the Abuse Potentiality of Morphinelike Drugs (Methods Used in Man) , 1977 .

[20]  H. Isbell,et al.  The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide , 1964, Psychopharmacologia.

[21]  S. Kollins,et al.  Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. , 1998, Experimental and clinical psychopharmacology.

[22]  Felix Hasler,et al.  Acute psychological and physiological effects of psilocybin in healthy humans : a double-blind , placebo-controlled dose – effect study , 2004 .

[23]  Felix Hasler,et al.  Modulating the Rate and Rhythmicity of Perceptual Rivalry Alternations with the Mixed 5-HT2A and 5-HT1A Agonist Psilocybin , 2005, Neuropsychopharmacology.

[24]  R. Strassman,et al.  LSD, Spirituality, and the Creative Process , 2003 .

[25]  Huston Smith.  Cleansing the Doors of Perception: The Religious Significance of Entheogenic Plants and Chemicals , 2003 .

[26]  R. Piedmont.  Cross-cultural generalizability of the Spiritual Transcendence Scale to the Philippines: Spirituality as a human universal , 2007 .

[27]  Andreas Bäbler,et al.  Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.

[28]  J. Halpern,et al.  Do hallucinogens cause residual neuropsychological toxicity? , 1999, Drug and alcohol dependence.

[29]  R. Piedmont.  Does Spirituality Represent the Sixth Factor of Personality? Spiritual Transcendence and the Five-Factor Model , 1999 .

[30]  S. Kollins,et al.  Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. , 1998, Experimental and clinical psychopharmacology.

[31]  L. Lunsky.  The Varieties of Psychedelic Experience. , 1967 .

[32]  H. Isbell,et al.  Comparison of psilocin with psilocybin, mescaline and LSD-25 , 2004, Psychopharmacologia.

[33]  C. Haertzen,et al.  Development of Scales Based on Patterns of Drug Effects, Using the Addiction Research Center Inventory (ARCI) , 1966, Psychological reports.

[34]  R. Yensen,et al.  Thirty Years of Psychedelic Research : The Spring Grove Experiment and its Sequels , 2003 .

[35]  Peter C. Hill,et al.  The psychology of religion : an empirical approach , 1986 .

[36]  Pahnke Wn.  Psychedelic drugs and mystical experience. , 1969 .

[37]  H. Isbell.  Comparison of the reactions induced by psilocybin and LSD-25 in man , 2004, Psychopharmacologia.

[38]  G. H. Litwin,et al.  REACTIONS TO PSILOCYBJN ADMINISTERED IN A SUPPORTIVE ENVIRONMENT , 1963, The Journal of nervous and mental disease.

[39]  D. Jasinski,et al.  Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man , 1971, Clinical pharmacology and therapeutics.

[40]  P. Watson,et al.  Quasi-Experimental Elicitation of the Differential Report of Religious Experience Among Intrinsic and Indiscriminately Pro-Religious Types , 1990, Dimensions of Mystical Experiences.

[41]  P. Costa,et al.  Revised NEO Personality Inventory (NEO-PI-R) and NEO-Five-Factor Inventory (NEO-FFI) , 1992 .

[42]  C. R. Atwell,et al.  Experimental psychiatry. V. Psilocybine, a new psychotogenic drug. , 1960, The New England journal of medicine.

[43]  P. Watson,et al.  Dimensions of the Mysticism Scale: Confirming the Three‐Factor Structure in the United States and Iran , 2001 .

[44]  J. Houston,et al.  The Varieties of Psychedelic Experience , 1973 .

[45]  R. Kellner,et al.  Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. , 1994, Archives of general psychiatry.

[46]  L. Hollister.  Clinical, biochemical and psychologic effects of psilocybin. , 1961, Archives internationales de pharmacodynamie et de therapie.

[47]  P. Stamets.  Psilocybin mushrooms of the world : an identification guide , 1996 .

[48]  H. Leuner.  Halluzinogene : psychische Grenzzustände in Forschung u. Psychotherapie , 1981 .

[49]  Huston Smith.  Do Drugs Have Religious Import , 1964 .

[50]  R. Doblin.  PAHNKE'S "GOOD FRIDAY EXPERIMENT' A LONG-TERM FOLLOW-UP AND METHODOLOGICAL CRITIQUE , 1991 .

[51]  A Dittrich,et al.  The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans , 1998, Pharmacopsychiatry.

[52]  Huston Smith,et al.  Psychoactive Sacramentals: Essays on Entheogens and Religion , 2001 .

[53]  E. Gouzoulis-Mayfrank,et al.  Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers Results of an experimental double-blind placebo-controlled study , 1999, Psychopharmacology.

[54]  Robert A Emmons,et al.  The psychology of religion. , 2003, Annual review of psychology.

[55]  A. Kurland,et al.  Methylenedioxyamphetamine (MDA)–Subjective Effects , 1974 .